65,437 trials
Infections, Papillomavirus
Primary: Number of Subjects With HPV DNA in Cervical Samples by Hybrid Capture 2 Test (HCII) — 615; 828; 24; 418 Participants
Parkinson's Disease (PD)
Primary: Maximum Observed Plasma Drug Concentration (Cmax) — 1.28; 1.45; 1.42; 0.439 ng/mL
Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Develop Skin Rash — 60.0; 69.2; 73.1 percentage of participants — p=0.481
Hematological Malignancies
Primary: Overall Survival at 6 Months Post-transplant in Patients Receiving a Partially-matched Related Donor Allogeneic Transplant After Reduced-intensity Conditioning — 22…
Malaria
Primary: Cotton Yields — 544; 548 kg
Diabetes · Hyperglycemia
Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min
Complicated Intra-abdominal Infection
Primary: The Percentage of Subjects With Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population — 83.0; 87.3 percentage…
Multiple Myeloma · Non-Hodgkin Lymphoma · Hodgkin Disease
Primary: Number of Patients Who Achieved Mobilization Success of Hematopoietic Stem Cells in Patients With Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease…
Complicated Urinary Tract Infection
Primary: Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-Treat (mMITT) Population — 83.1; 76.3 percentage of patients
Prostatic Neoplasms
Primary: Progression Free Rate (PFR) at 12 Weeks — 25.9; 0.0; 0.0; NA percentage of participants — p=0.0577
Complicated Urinary Tract Infection · Pyelonephritis
Primary: The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the…
Ovarian Neoplasms · Peritoneal Neoplasms
Primary: PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria. — 17.2…
Pain
Primary: The Number of Participants With Adverse Events as a Measure of Safety. — 3; 2; 8; 8 participants
Parkinson's Disease
Primary: Cmax - Maximum Plasma Concentration of BIA 9-1067 — 1108; 559 ng/mL
Recurrent Fallopian Tube Cancer · Recurrent Ovarian Epithelial Cancer · Recurrent Primary Peritoneal Cavity Cancer
Primary: Objective Response (Partial Response or Complete Response) as Per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 3.6 percentage of evalubale patients